| 1 |
34240438 | Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report. | 2022 Feb |
1 |
| 2 |
35443836 | Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study. | 2022 Jan-Dec |
4 |
| 3 |
35495754 | The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. | 2022 |
2 |
| 4 |
32949176 | Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. | 2021 Mar |
1 |
| 5 |
33422069 | Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe. | 2021 Jan 9 |
2 |
| 6 |
33536747 | A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. | 2021 |
2 |
| 7 |
33548989 | Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review. | 2021 Jun |
2 |
| 8 |
33740528 | A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. | 2021 Jun |
2 |
| 9 |
33755971 | Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis. | 2021 Mar |
5 |
| 10 |
33791214 | Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study. | 2021 |
1 |
| 11 |
33828975 | The Value of Anlotinib in the Treatment of Intractable Brain Edema: Two Case Reports. | 2021 |
2 |
| 12 |
33832949 | Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. | 2021 Jul 1 |
1 |
| 13 |
34012799 | Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. | 2021 Apr |
2 |
| 14 |
34510760 | Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer. | 2021 Oct |
1 |
| 15 |
34532490 | Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report. | 2021 Aug |
2 |
| 16 |
34692475 | Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. | 2021 |
4 |
| 17 |
31630895 | Corrigendum to "Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1" [Gene 654 (2018) 77-86]. | 2020 Jan 10 |
1 |
| 18 |
32266457 | A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors. | 2020 May |
1 |
| 19 |
32415222 | Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. | 2020 Oct |
1 |
| 20 |
32587778 | Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling. | 2020 May 15 |
1 |
| 21 |
32709873 | Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. | 2020 Jul 24 |
2 |
| 22 |
32724339 | Anlotinib as a molecular targeted therapy for tumors. | 2020 Aug |
2 |
| 23 |
30588030 | Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review. | 2019 |
2 |
| 24 |
30719715 | Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. | 2019 Aug 15 |
3 |
| 25 |
29764596 | [A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation
Treated with Anlotinib]. | 2018 May 20 |
2 |
| 26 |
30032842 | Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. | 2018 Aug |
1 |
| 27 |
30231931 | Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. | 2018 Sep 19 |
2 |
| 28 |
27716285 | Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. | 2016 Oct 4 |
1 |